Employer Innovation
Series EN · The State of Metabolic Health in America, 2026 Baseline Edition
Overview
Employer benefit design decisions for GLP-1 medications, including coverage continuation intent, utilization control tightening, and variation across employer surveys with different populations and question designs.
This series contains 10 metrics in the 2026 Baseline Edition. Each metric cites a primary source. Where sources disagree, both figures and the reason for the discrepancy are documented rather than reconciled.
Metrics in This Series
Methodological Notes
Metrics in this series draw on federal surveys, administrative data, and peer-reviewed literature. Where two sources report different figures for the same condition, both are documented with the reason for the discrepancy — typically differences in survey population, measurement method, or case definition.
See Methodology for the full source selection criteria, metric ID system, and conflict resolution approach.
Data Gaps in This Series
Specific data gaps for this series are documented on the Data Gaps page. The report names what is not measured rather than estimating missing values.